GlassScriptPhysician profile
Jenny Mcdade Despotovic
NPI 1326298126
$58,898.30
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,672 · 2020: $30K · 2021: $5,965 · 2022: $17K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26,361.31 | 2019-2022 | |
| Agios Pharmaceuticals, INC. | $15,012.48 | 2020-2022 | |
| Dova Pharmaceuticals | $7,561.53 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $5,400.00 | 2022 | |
| Sobi, INC | $2,775.00 | 2022 | |
| Amgen INC. | $1,787.98 | 2019-2022 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Despotovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.